MicroRNA regulation of proteoglycan function in cancer

FEBS Journal

Volumn 281, Issue 22, 2014, Pages 5009-5022

  Ibrahim, Sherif A ^a   Hassan, Hebatallah ^a   Götte, Martin ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

cancer; cancer stem cells; cerna; decorin; glypican; heparan sulfate; heparanase; microrna; post transcriptional regulation; syndecan

Indexed keywords

MEMBRANE PROTEIN; MICRORNA; PROTEOGLYCAN;

ANIMAL; DISEASE COURSE; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE;

ANIMALS; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE GLYCOPROTEINS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEOGLYCANS; RNA INTERFERENCE;

EID: 84910125004     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13026     Document Type: Review

References (105)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, &, Bray F,. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr, accessed on 14/05/2014.
2. Marcucci F, Bellone M, Caserta CA, &, Corti A, (2014) Pushing tumor cells towards a malignant phenotype: Stimuli from the microenvironment, intercellular communications and alternative roads. Int J Cancer 135, 1265-1276.
3. Hanahan D, &, Weinberg RA, (2011) Hallmarks of cancer: The next generation. Cell 144, 646-674.
4. Theocharis AD, Skandalis SS, Tzanakakis GN, &, Karamanos NK, (2010) Proteoglycans in health and disease: Novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277, 3904-3923.
5. Hassan H, Greve B, Pavao MS, Kiesel L, Ibrahim SA, &, Götte M, (2013) Syndecan-1 modulates β-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation. FEBS J 280, 2216-2227.
6. Ramani VC, Purushothaman A, Stewart MD, Thompson CA, Vlodavsky I, Au JL, &, Sanderson RD, (2013) The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J 280, 2294-2306.
7. Xiong A, Kundu S, &, Forsberg-Nilsson K, (2014) Heparan sulfate in regulation of neural differentiation and glioma development. FEBS J 281, 4993-5008.
8. Sofeu Feugaing DD, Götte M, &, Viola M, (2013) More than matrix: The multifaceted role of decorin in cancer. Eur J Cell Biol 92, 1-11.
9. Wight TN, Kinsella MG, Evanko SP, Potter-Perigo S, &, Merrilees MJ, (2014) Versican and the regulation of cell phenotype in disease. Biochim Biophys Acta 1840, 2441-2451.
10. Götte M, Kersting C, Ruggiero M, Tio J, Tulusan AH, Kiesel L, &, Wülfing P, (2006) Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res 26, 621-627.
11. Theocharis AD, Gialeli C, Bouris P, Giannopoulou E, Skandalis SS, Aletras AJ, Iozzo RV, &, Karamanos NK, (2014) Cell-matrix interactions: Focus on proteoglycan-proteinase interplays and pharmacological targeting in cancer. FEBS J 281, 5023-5042.
12. Kumar AV, Salem Gassar E, Spillmann D, Stock C, Sen YP, Zhang T, Van Kuppevelt TH, Hülsewig C, Koszlowski E, Pavao MS, et al,. (2014) HS3ST2 modulates breast cancer cell invasiveness via MAP kinase- and Tcf4 (Tcf7 l2)-dependent regulation of protease and cadherin expression. Int J Cancer 135, 2579-2592.
13. Vigetti D, Viola M, Karousou E, Deleonibus S, Karamanou K, Luca GD, &, Passi A, (2014) Epigenetics in extracellular matrix remodeling and hyaluronan metabolism. FEBS J 281, 4980-4992.
14. Bartel DP, (2009) MicroRNAs: Target recognition and regulatory functions. Cell 136, 215-233.
15. Treiber T, Treiber N, &, Meister G, (2012) Regulation of microRNA biogenesis and function. Thromb Haemost 107, 605-610.
16. Lujambio A, &, Lowe SW, (2012) The microcosmos of cancer. Nature 482, 347-355.
17. Lee Y, Kim M, Han J, Yeom K-H, Lee S, Baek SH, &, Kim VN, (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23, 4051-4060.
18. Bernstein E, Caudy AA, Hammond SM, &, Hannon GJ, (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409, 363-366.
19. Matranga C, Tomari Y, Shin C, Bartel DP, &, Zamore PD, (2005) Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123, 607-620.
20. Chekulaeva M, Mathys H, Zipprich JT, Attig J, Colic M, Parker R, &, Filipowicz W, (2011) miRNA repression involves GW182-mediated recruitment of CCR4-NOT through conserved W-containing motifs. Nat Struct Mol Biol 18, 1218-1226.
21. Fabian MR, Cieplak MK, Frank F, Morita M, Green J, Srikumar T, Nagar B, Yamamoto T, Raught B, Duchaine TF, et al,. (2011) miRNA-mediated deadenylation is orchestrated by GW182 through two conserved motifs that interact with CCR4-NOT. Nat Struct Mol Biol 18, 1211-1217.
22. Meister G, (2013) Argonaute proteins: Functional insights and emerging roles. Nat Rev Genet 14, 447-459.
23. Vasudevan S, Tong Y, &, Steitz JA, (2007) Switching from repression to activation: microRNAs can upregulate translation. Science 318, 1931-1934.
24. Tsai NP, Lin YL, &, Wei LN, (2009) MicroRNA mir-346 targets the 5′-untranslated region of receptorinteracting protein 140 (RIP140) mRNA and up-regulates its protein expression. Biochem J 424, 411-418.
25. Ibrahim SA, Hassan H, &, Götte M, (2014) MicroRNA-dependent targeting of the extracellular matrix as a mechanism of regulating cell behavior. Biochim Biophys Acta 1840, 2609-2620.
26. Su N, Wang Y, Qian M, &, Deng M, (2010) Combinatorial regulation of transcription factors and microRNAs. BMC Syst Biol 4, 150.
27. Sato F, Tsuchiya S, Meltzer SJ, &, Shimizu K, (2011) MicroRNAs and epigenetics. FEBS J 278, 1598-1609.
28. Griffiths-Jones S, (2004) The microRNA registry. Nucleic Acids Res 32 (Database Issue), D109-D111.
29. Zhou P, Xu W, Peng X, Luo Z, Xing Q, Chen X, Hou C, Liang W, Zhou J, Wu X, et al,. (2013) Large-scale screens of miRNA-mRNA interactions unveiled that the 3′UTR of a gene is targeted by multiple miRNAs. PLoS One 8, e68204.
30. Hedbäck N, Jensen DH, Specht L, Fiehn AM, Therkildsen MH, Friis-Hansen L, Dabelsteen E, &, von Buchwald C, (2014) MiR-21 expression in the tumor stroma of oral squamous cell carcinoma: An independent biomarker of disease free survival. PLoS One 9, e95193.
31. Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG, Alvarez RH, Valero V, et al,. (2014) High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2 + inflammatory breast cancer. PLoS One 9, e83113.
32. Lu J, Xu X, Liu X, Peng Y, Zhang B, Wang L, Luo H, Peng X, Li G, Tian W, et al,. (2014) Predictive value of miR-9 as a potential biomarker for nasopharyngeal carcinoma metastasis. Br J Cancer 110, 392-398.
33. Huang SP, Lévesque E, Guillemette C, Yu CC, Huang CY, Lin VC, Chung IC, Chen LC, Laverdière I, Lacombe L, et al,. (2014) Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. Int J Cancer 135, 2661-2667.
34. Omura T, Shimada Y, Nagata T, Okumura T, Fukuoka J, Yamagishi F, Tajika S, Nakajima S, Kawabe A, &, Tsukada K, (2014) Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy. Oncol Rep 31, 613-618.
35. Odenthal M, Bollschweiler E, Grimminger PP, Schröder W, Brabender J, Drebber U, Hölscher AH, Metzger R, &, Vallböhmer D, (2013) MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response. Int J Cancer 133, 2454-2463.
36. Heneghan HM, Miller N, Kelly R, Newell J, &, Kerin MJ, (2010) Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 15, 673-682.
37. Hao J, Zhang Y, Deng M, Ye R, Zhao S, Wang Y, Li J, &, Zhao Z, (2014) MicroRNA control of epithelial-mesenchymal transition in cancer stem cells. Int J Cancer 135, 1019-1027.
38. Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, Dreier R, Kelsch R, Fischgräbe J, Smollich M, Rossi LH, et al,. (2009) Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 30, 397-407.
39. Horváth Z, Kovalszky I, Fullár A, Kiss K, Schaff Z, Iozzo RV, &, Baghy K, (2014) Decorin deficiency promotes hepatic carcinogenesis. Matrix Biol 35, 194-205.
40. Ibrahim SA, Hassan H, Vilardo L, Kumar SK, Kumar AV, Kelsch R, Schneider C, Kiesel L, Eich HT, Zucchi I, et al,. (2013) Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling. PLoS One 8, e85737.
41. McDermott SP, Ranheim EA, Leatherberry VS, Khwaja SS, Klos KS, &, Alexander CM, (2007) Juvenile syndecan-1 null mice are protected from carcinogen-induced tumor development. Oncogene 26, 1407-1416.
42. Götte M, Kersting C, Radke I, Kiesel L, &, Wülfing P, (2007) An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res 9, R8.
43. Beauvais DM, Ell BJ, McWhorter AR, &, Rapraeger AC, (2009) Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 206, 691-705.
44. Iozzo RV, &, Sanderson RD, (2011) Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15, 1013-1031.
45. Götte M, &, Yip GW, (2006) Heparanase, hyaluronan, and CD44 in cancers: A breast carcinoma perspective. Cancer Res 66, 10233-10237.
46. Ibrahim SA, Yip GW, Stock C, Pan JW, Neubauer C, Poeter M, Pupjalis D, Koo CY, Kelsch R, Schüle R, et al,. (2012) Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism. Int J Cancer 131, E884-E896.
47. Korpetinou A, Skandalis SS, Moustakas A, Happonen KE, Tveit H, Prydz K, Labropoulou VT, Giannopoulou E, Kalofonos HP, Blom AM, et al,. (2013) Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells. PLoS One 8, e78157.
48. Kozlowski EO, Pavão MS, &, Borsig L, (2011) Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin. J Thromb Haemost 9, 1807-1815.
49. Silver DJ, Siebzehnrubl FA, Schildts MJ, Yachnis AT, Smith GM, Smith AA, Scheffler B, Reynolds BA, Silver J, &, Steindler DA, (2013) Chondroitin sulfate proteoglycans potently inhibit invasion and serve as a central organizer of the brain tumor microenvironment. J Neurosci 33, 15603-15617.
50. Merline R, Moreth K, Beckmann J, Nastase MV, Zeng-Brouwers J, Tralhão JG, Lemarchand P, Pfeilschifter J, Schaefer RM, Iozzo RV, et al,. (2011) Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci Signal 4, ra75.
51. Kharabi Masouleh B, Ten Dam GB, Wild MK, Seelige R, van der Vlag J, Rops AL, Echtermeyer FG, Vestweber D, van Kuppevelt TH, Kiesel L, et al,. (2009) Role of the heparan sulfate proteoglycan syndecan-1 (CD138) in delayed-type hypersensitivity. J Immunol 182, 4985-4993.
52. Bocian C, Urbanowitz AK, Owens RT, Iozzo RV, Götte M, &, Seidler DG, (2013) Decorin potentiates interferon-γ activity in a model of allergic inflammation. J Biol Chem 288, 12699-12711.
53. Chou J, Shahi P, &, Werb Z, (2013) microRNA-mediated regulation of the tumor microenvironment. Cell Cycle 12, 3262-3271.
54. Christianson HC, Svensson KJ, van Kuppevelt TH, Li JP, &, Belting M, (2013) Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proc Natl Acad Sci U S A 110, 17380-17385.
55. Filmus J, &, Capurro M, (2013) Glypican-3: A marker and a therapeutic target in hepatocellular carcinoma. FEBS J 280, 2471-2476.
56. Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, &, Schlessinger D, (1996) Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 12, 241-247.
57. Maurel M, Jalvy S, Ladeiro Y, Combe C, Vachet L, Sagliocco F, Bioulac-Sage P, Pitard V, Jacquemin-Sablon H, Zucman-Rossi J, et al,. (2013) A functional screening identifies five microRNAs controlling glypican-3: Role of miR-1271 down-regulation in hepatocellular carcinoma. Hepatology 57, 195-204.
58. Maurel M, Dejeans N, Taouji S, Chevet E, &, Grosset CF, (2013) MicroRNA-1291-mediated silencing of IRE1alpha enhances glypican-3 expression. RNA 19, 778-788.
59. Miao HL, Lei CJ, Qiu ZD, Liu ZK, Li R, Bao ST, &, Li MY, (2014) MicroRNA-520c-3p inhibits hepatocellular carcinoma cell proliferation and invasion through induction of cell apoptosis by targeting glypican-3. Hepatol Res 44, 338-348.
60. Huang N, Lin J, Ruan J, Su N, Qing R, Liu F, He B, Lv C, Zheng D, &, Luo R, (2012) MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett 586, 884-891.
61. Chamorro-Jorganes A, Araldi E, Rotllan N, Cirera-Salinas D, &, Suárez Y, (2014) Autoregulation of glypican-1 by intronic microRNA-149 fine tunes the angiogenic response to FGF2 in human endothelial cells. J Cell Sci 127, 1169-1178.
62. Feng C, Li J, Ruan J, &, Ding K, (2012) MicroRNA-125a inhibits cell growth by targeting glypican-4. Glycoconj J 29, 503-511.
63. Yiu GK, Kaunisto A, Chin YR, &, Toker A, (2011) NFAT promotes carcinoma invasive migration through glypican-6. Biochem J 440, 157-166.
64. Alshalalfa M, Bader GD, Bismar TA, &, Alhajj R, (2013) Coordinate microRNA-mediated regulation of protein complexes in prostate cancer. PLoS One 8, e84261.
65. Hannafon BN, Sebastiani P, de las Morenas A, Lu J, &, Rosenberg CL, (2011) Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res 13, R24.
66. Li R, Zhang L, Jia L, Duan Y, Li Y, Wang J, Bao L, &, Sha N, (2014) MicroRNA-143 targets Syndecan-1 to repress cell growth in melanoma. PLoS One 9, e94855.
67. Schneider C, Kässens N, Greve B, Hassan H, Schüring AN, Starzinski-Powitz A, Kiesel L, Seidler DG, &, Götte M, (2013) Targeting of syndecan-1 by micro-ribonucleic acid miR-10b modulates invasiveness of endometriotic cells via dysregulation of the proteolytic milieu and interleukin-6 secretion. Fertil Steril 99, 871-881.e1.
68. Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, Ivarsson Y, Depoortere F, Coomans C, Vermeiren E, et al,. (2012) Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat Cell Biol 14, 677-685.
69. Kharaziha P, Ceder S, Li Q, &, Panaretakis T, (2012) Tumor-derived exosomes: A message in a bottle. Biochim Biophys Acta 1826, 103-111.
70. Soria-Valles C, Gutiérrez-Fernández A, Guiu M, Mari B, Fueyo A, Gomis RR, &, Lõpez-Otín C, (2014) The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21. Oncogene 33, 3054-3063.
71. Benet M, Dulman RY, Suzme R, de Miera EV, Vega ME, Nguyen T, Zavadil J, &, Pellicer A, (2012) Wild type N-ras displays anti-malignant properties, in part by downregulating decorin. J Cell Physiol 227, 2341-2351.
72. Lee DY, Jeyapalan Z, Fang L, Yang J, Zhang Y, Yee AY, Li M, Du WW, Shatseva T, &, Yang BB, (2010) Expression of versican 3′-untranslated region modulates endogenous microRNA functions. PLoS One 5, e13599.
73. Fang L, Du WW, Yang X, Chen K, Ghanekar A, Levy G, Yang W, Yee AJ, Lu WY, Xuan JW, et al,. (2013) Versican 3′-untranslated region (3′-UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activity. FASEB J 27, 907-919.
74. Yang W, &, Yee AJ, (2014) Versican 3′-untranslated region (3′UTR) promotes dermal wound repair and fibroblast migration by regulating miRNA activity. Biochim Biophys Acta 1843, 1373-1385.
75. Ebert MS, &, Sharp PA, (2010) Emerging roles for natural microRNA sponges. Curr Biol 20, R858-R861.
76. Kosik KS, (2013) Molecular biology: circles reshape the RNA world. Nature 495, 322-324.
77. Tay Y, Rinn J, &, Pandolfi PP, (2014) The multilayered complexity of ceRNA crosstalk and competition. Nature 505, 344-352.
78. Denzler R, Agarwal V, Stefano J, Bartel DP, &, Stoffel M, (2014) Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance. Mol Cell 54, 766-776.
79. Rutnam ZJ, Wight TN, &, Yang BB, (2013) miRNAs regulate expression and function of extracellular matrix molecules. Matrix Biol 32, 74-85.
80. Hu H, Li S, Cui X, Lv X, Jiao Y, Yu F, Yao H, Song E, Chen Y, Wang M, et al,. (2013) The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2). J Biol Chem 288, 10973-10985.
81. Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, Gu J, Wu X, &, Lu K, (2010) Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res 70, 9765-9776.
82. Permuth-Wey J, Chen Z, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Chanock SJ, Cramer DW, Cunningham JM, et al,. & Ovarian Cancer Association Consortium (OCAC). (2011) MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 20: 1793-1797.
83. Shi X, Su S, Long J, Mei B, &, Chen Y, (2011) MicroRNA-191 targets N-deacetylase/N-sulfotransferase 1 and promotes cell growth in human gastric carcinoma cell line MGC803. Acta Biochim Biophys Sin (Shanghai) 43, 849-856.
84. Kasza Z, Fredlund Fuchs P, Tamm C, Eriksson AS, O'Callaghan P, Heindryckx F, Spillmann D, Larsson E, Le Jan S, Eriksson I, et al,. (2013) MicroRNA-24 suppression of N-deacetylase/N-sulfotransferase-1 (NDST1) reduces endothelial cell responsiveness to VEGFA. J Biol Chem 288, 25956-25963.
85. Vivès RR, Seffouh A, &, Lortat-Jacob H, (2014) Post-synthetic regulation of hs structure: The yin and yang of the sulfs in cancer. Front Oncol 3, 331.
86. Bao L, Yan Y, Xu C, Ji W, Shen S, Xu G, Zeng Y, Sun B, Qian H, Chen L, et al,. (2013) MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett 337, 226-236.
87. Takei Y, Takigahira M, Mihara K, Tarumi Y, &, Yanagihara K, (2011) The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. Cancer Res 71, 1442-1453.
88. Tang D, Zhang Q, Zhao S, Wang J, Lu K, Song Y, Zhao L, Kang X, Wang J, Xu S, et al,. (2013) The expression and clinical significance of microRNA-1258 and heparanase in human breast cancer. Clin Biochem 46, 926-932.
89. Liu H, Chen X, Gao W, &, Jiang G, (2012) The expression of heparanase and microRNA-1258 in human non-small cell lung cancer. Tumour Biol 33, 1327-1334.
90. Zhang L, Sullivan PS, Goodman JC, Gunaratne PH, &, Marchetti D, (2011) MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res 71, 645-654.
91. Chérel M, Gouard S, Gaschet J, Saï-Maurel C, Bruchertseifer F, Morgenstern A, Bourgeois M, Gestin JF, Bodéré FK, Barbet J, et al,. (2013) 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. Nucl Med 54, 1597-1604.
92. Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, et al,. (2009) The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 15, 4028-4037.
93. Gao W, Kim H, Feng M, Phung Y, Xavier CP, Rubin JS, &, Ho M, (2014) Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology 60, 576-587.
94. Meirovitz A, Hermano E, Lerner I, Zcharia E, Pisano C, Peretz T, &, Elkin M, (2011) Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res 71, 2772-2780.
95. Dredge K, Hammond E, Davis K, Li CP, Liu L, Johnstone K, Handley P, Wimmer N, Gonda TJ, Gautam A, et al,. (2010) The PG500 series: Novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest New Drugs 28, 276-283.
96. Cassinelli G, Lanzi C, Tortoreto M, Cominetti D, Petrangolini G, Favini E, Zaffaroni N, Pisano C, Penco S, Vlodavsky I, et al,. (2013) Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem Pharmacol 85, 1424-1432.
97. Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C, Carminati P, Tortoreto M, et al,. (2011) SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 17, 1382-1393.
98. Malavaki CJ, Roussidis AE, Gialeli C, Kletsas D, Tsegenidis T, Theocharis AD, Tzanakakis GN, &, Karamanos NK, (2013) Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells. FEBS J 280, 2477-2489.
99. Suarez ER, Paredes-Gamero EJ, Del Giglio A, Tersariol IL, Nader HB, &, Pinhal MA, (2013) Heparan sulfate mediates trastuzumab effect in breast cancer cells. BMC Cancer 13, 444.
100. Li Z, &, Rana TM, (2014) Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 13, 622-638.
101. Asuthkar S, Velpula KK, Nalla AK, Gogineni VR, Gondi CS, &, Rao JS, (2014) Irradiation-induced angiogenesis is associated with an MMP-9-miR-494-syndecan-1 regulatory loop in medulloblastoma cells. Oncogene 33, 1922-1933.
102. Liu XY, Tang QS, Chen HC, Jiang XL, &, Fang H, (2013) Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity. Int J Biol Sci 9, 564-577.
103. Liu X, Fang H, Chen H, Jiang X, Fang D, Wang Y, &, Zhu D, (2012) An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS One 7, e38659.
104. Christianson HC, &, Belting M, (2014) Heparan sulfate proteoglycan as a cell-surface endocytosis receptor. Matrix Biol 35, 51-55.
105. Liu P, Gou M, Yi T, Qi X, Xie C, Zhou S, Deng H, Wei Y, &, Zhao X, (2012) The enhanced antitumor effects of biodegradable cationic heparin-polyethyleneimine nanogels delivering HSulf-1 gene combined with cisplatin on ovarian cancer. Int J Oncol 41, 1504-1512.